‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTUREnetwork
British Journal of Dermatology2014Vol. 171(5), pp. 1189–1196
Citations Over TimeTop 10% of 2014 papers
J. M. P. A. van den Reek, Jeffrey Zweegers, Wietske Kievit, Marisol E. Otero, P.P.M. van Lümig, R.J.B. Driessen, Paul M. Ossenkoppele, M.D. Njoo, J.M. Mommers, M.I.A. Koetsier, W.P. Arnold, B.A.M. Sybrandy‐Fleuren, A.L.A. Kuijpers, M.P.M. Andriessen, P.C.M. van de Kerkhof, Marieke M.B. Seyger, E.M.G.J. de Jong
Abstract
Ustekinumab showed a better overall drug survival than etanercept, and a trend towards a better overall drug survival than adalimumab. After 1 year, patients reported to be 'happy' in 79% of episodes and 'unhappy' in 21%. We introduced the new concept of 'happy' drug survival because the proportion of on-drug patients with good quality of life is an important indicator for treatment success.
Related Papers
- → Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab(2017)22 cited
- → PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis(2017)15 cited
- → CP-080 Comparative effectiveness of ustekinumab and adalimumab in psoriasis patients previously treated with etanercept(2016)
- → Su1875 – Development of Targeted Therapeutic Antibodies for the Treatment of Inflammatory Bowel Disease(2019)
- → Su1873 – Remission to Vedolizumab is Not Higher in TNF-Naive Compared to TNF-Pretreated Patients with Crohn’s Disease(2019)